Ainos Inc. has announced a significant regulatory approval, as its lead drug candidate, VELDONA®, a low-dose oral interferon, has received clearance to begin clinical trials in Taiwan. The trials will focus on treating HIV-related oral warts and primary Sjögren's syndrome (PSS). This milestone marks an important step forward for Ainos in its transition from research and development to commercial execution. The company is also preparing for the launch of scaled pilot programs in the latter half of 2025, leveraging its AI Nose technology across various industries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.